Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.

Toxicological sciences : an official journal of the Society of Toxicology 20140101

Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.

Toxicological sciences : an official journal of the Society of Toxicology 20131201

Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

Brain research 20130225

Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity.

Toxicology letters 20121017

Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes.

The international journal of neuropsychopharmacology 20121001

The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.

Toxicologic pathology 20120801

Dopamine, corticostriatal connectivity, and intertemporal choice.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20120704

Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.

European journal of neurology 20120601

Ultraviolet B radiation differentially modifies catechol-O-methyltransferase activity in keratinocytes and melanoma cells.

Photodermatology, photoimmunology & photomedicine 20120601

The ethics of elective psychopharmacology.

The international journal of neuropsychopharmacology 20120501

Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice.

Behavioural brain research 20120317

COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition.

Biological psychiatry 20120315

Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.

ACS chemical neuroscience 20120215

Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.

Analytica chimica acta 20120113

Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.

Drug metabolism and pharmacokinetics 20120101

Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats.

Psychopharmacology 20120101

Neurocognitive correlates of apathy and anxiety in Parkinson's disease.

Parkinson's disease 20120101

The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.

PloS one 20120101

Risk of falls in Parkinson's disease: a cross-sectional study of 160 patients.

Parkinson's disease 20120101

A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.

Clinical neuropharmacology 20120101

[A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20120101

Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia.

Current molecular medicine 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

2'-Deoxyguanosine as a surrogate trapping agent for DNA reactive drug metabolites.

Toxicology letters 20111110

Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development.

The Journal of biological chemistry 20111007

A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20110901

Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation.

Drug metabolism and disposition: the biological fate of chemicals 20110801

Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110701

Species independence in brain tissue binding using brain homogenates.

Drug metabolism and disposition: the biological fate of chemicals 20110701

Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia.

Pharmacogenomics 20110401

Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20110301

D-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: a novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry.

Toxicology in vitro : an international journal published in association with BIBRA 20110201

Kleptomania treated with tolcapone, a catechol-O-methyl-transferase (COMT) inhibitor.

Progress in neuro-psychopharmacology & biological psychiatry 20110115

Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone.

Neuroscience research 20110101

Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).

Movement disorders : official journal of the Movement Disorder Society 20110101

Relation of subjective quality of life to motor symptom profile in Parkinson's disease.

Parkinson's disease 20110101

Available and emerging treatments for Parkinson's disease: a review.

Drug design, development and therapy 20110101

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.

Neuropsychiatric disease and treatment 20110101

Network neighbors of drug targets contribute to drug side-effect similarity.

PloS one 20110101

Impact of external cue validity on driving performance in Parkinson's disease.

Parkinson's disease 20110101

Factor analysis of attentional set-shifting performance in young and aged mice.

Behavioral and brain functions : BBF 20110101

Identification and categorization of liver toxicity markers induced by a related pair of drugs.

International journal of molecular sciences 20110101

Pharmacologic safety concerns in Parkinson's disease: facts and insights.

The International journal of neuroscience 20110101

Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

Journal of drug delivery 20110101

Drug-resistant tuberculosis: emerging treatment options.

Clinical pharmacology : advances and applications 20110101

Activation of nitrofurazone by azoreductases: multiple activities in one enzyme.

Scientific reports 20110101

Comparison of in vitro cell models in predicting in vivo brain entry of drugs.

International journal of pharmaceutics 20101215

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

Toxicological sciences : an official journal of the Society of Toxicology 20101201

A predictive ligand-based Bayesian model for human drug-induced liver injury.

Drug metabolism and disposition: the biological fate of chemicals 20101201

Systemic catechol-O-methyl transferase inhibition enables the D1 agonist radiotracer R-[11C]SKF 82957.

Nuclear medicine and biology 20101001

Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence.

The American journal of geriatric pharmacotherapy 20100801

Transdermal rotigotine for the perioperative management of Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20100701

Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.

The Journal of biological chemistry 20100514

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Clinical neuropharmacology 20100501

Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.

Clinical neuropharmacology 20100501

Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

Journal of medicinal chemistry 20100422

Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.

Neuroscience letters 20100114

Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.

Toxicological sciences : an official journal of the Society of Toxicology 20100101

Tolcapone improves sleep in patients with advanced Parkinson's disease (PD).

Archives of gerontology and geriatrics 20100101

Quality of life in Parkinson's disease patients following adjunctive tolcapone therapy: results of an open-label, multicenter, community-based trial.

CNS spectrums 20100101

Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models.

PloS one 20100101

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.

Core evidence 20100101

Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies.

PloS one 20100101

Binding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurements.

PloS one 20100101

Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Clinical interventions in aging 20100101

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).

Neuropsychiatric disease and treatment 20100101

The dopamine metabolite 3-methoxytyramine is a neuromodulator.

PloS one 20100101

Toxicology and safety of COMT inhibitors.

International review of neurobiology 20100101

Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.

International review of neurobiology 20100101

COMT Val158Met Polymorphism Modulates Cognitive Effects of Dietary Intervention.

Frontiers in aging neuroscience 20100101

Treatment of advanced Parkinson's disease.

Parkinson's disease 20100101

Membrane-Bound Catechol-O-Methyl Transferase in Cortical Neurons and Glial Cells is Intracellularly Oriented.

Frontiers in psychiatry 20100101

Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism.

Biological psychiatry 20091201

Management of antiparkinsonian therapy during chronic subthalamic stimulation in Parkinson's disease.

Parkinsonism & related disorders 20091201

Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study.

Biological psychiatry 20090915

Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090815

Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.

PLoS computational biology 20090701

Metabolism of protocatechuic acid influences fatty acid oxidation in rat heart: new anti-angina mechanism implication.

Biochemical pharmacology 20090315

'Bad guys' among the antiparkinsonian drugs.

Psychiatria Danubina 20090301

Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.

International journal of molecular sciences 20090301

Tolcapone in elderly patients with Parkinson's disease: a prospective open-label multicenter non-interventional trial.

Archives of gerontology and geriatrics 20090101

Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex.

Psychopharmacology 20090101

The liver toxicity biomarker study: phase I design and preliminary results.

Toxicologic pathology 20090101

Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.

BMC clinical pharmacology 20090101

Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.

Clinical interventions in aging 20090101

A review of ropinirole prolonged release in Parkinson's disease.

Clinical interventions in aging 20090101

Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Patient preference and adherence 20090101

Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Cardiovascular psychiatry and neurology 20090101

Antiparkinsonian therapy modifications in PD patients after STN DBS: a retrospective observational analysis.

Parkinsonism & related disorders 20081201

Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.

Archives of toxicology 20081201

Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081201

Does COMT val158met affect behavioral phenotypes: yes, no, maybe?

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081201

Clinical experience of tolcapone in advanced Parkinson's disease.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20081201

Suppression of beta oscillations in the subthalamic nucleus following cortical stimulation in humans.

The European journal of neuroscience 20081001

Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?

Experimental biology and medicine (Maywood, N.J.) 20080801

Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.

Brain : a journal of neurology 20080801

Current approaches to the treatment of Parkinson's disease.

Neuropsychiatric disease and treatment 20080801

Clinical insights into pharmacogenetics and schizophrenia, part 2.

The Journal of clinical psychiatry 20080601

Current status of symptomatic medical therapy in Parkinson's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20080401

Update on the use of pramipexole in the treatment of Parkinson's disease.

Neuropsychiatric disease and treatment 20080401

Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?

British journal of clinical pharmacology 20080301

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.

Neuropsychiatric disease and treatment 20080201

Drugs for Parkinson’s disease: levodopa is still the gold standard.

Neuropsychiatric disease and treatment 20080201

Rasagiline in treatment of Parkinson's disease.

Neuropsychiatric disease and treatment 20080201

Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.

CNS neuroscience & therapeutics 20080101

Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.

CNS drugs 20080101

Computational systems analysis of dopamine metabolism.

PloS one 20080101

Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease.

European neurology 20080101

Role of tolcapone in the treatment of Parkinson's disease.

Expert review of neurotherapeutics 20071201

Novel screening assay for antioxidant protection against peroxyl radical-induced loss of protein function.

Journal of pharmaceutical sciences 20071101

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease.

Journal of neurology, neurosurgery, and psychiatry 20070901

Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.

Therapeutics and clinical risk management 20070601

Continuous levodopa for advanced Parkinson's disease.

Neuropsychiatric disease and treatment 20070601

Tolcapone improves cognition and cortical information processing in normal human subjects.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070501

The endophenotype concept in psychiatric genetics.

Psychological medicine 20070201

Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20070101

Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion.

Neurochemistry international 20070101

Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

CNS drugs 20070101

Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

CNS drugs 20070101

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.

CNS drug reviews 20070101

Results from a 2-year centralized tolcapone liver enzyme monitoring program.

Clinical neuropharmacology 20070101

Tolcapone: an efficacy and safety review (2007).

Clinical neuropharmacology 20070101

New strategies in motor parkinsonism.

Parkinsonism & related disorders 20070101

[Tolcapone in the management of Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20070101

Utility of tolcapone in fluctuating Parkinson's disease.

Clinical interventions in aging 20061201

Tolcapone in the management of Parkinson's disease.

Expert opinion on pharmacotherapy 20061101

Bioactivation and hepatotoxicity of nitroaromatic drugs.

Current drug metabolism 20061001

Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.

Journal of the American Medical Directors Association 20060901

Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.

European journal of clinical pharmacology 20060601

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Neurology 20060411

Optimal design for multivariate response pharmacokinetic models.

Journal of pharmacokinetics and pharmacodynamics 20060401

Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.

Prescrire international 20060401

Lateralized semantic priming: modulation by levodopa, semantic distance, and participants' magical beliefs.

Neuropsychiatric disease and treatment 20060301

Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Clinical pharmacokinetics 20060101

Synthesis and biological evaluation of a novel series of 'ortho-nitrated' inhibitors of catechol-O-methyltransferase.

Journal of medicinal chemistry 20051215

Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.

Neurology 20051213

Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice.

Nature neuroscience 20051101

[Serious tolpcapone-induced hepatitis 17 months after commencing treatment].

Revue neurologique 20051101

Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.

Therapeutics and clinical risk management 20050901

Rapid simultaneous determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases.

Analytical biochemistry 20050601

Prediction of genotoxicity of chemical compounds by statistical learning methods.

Chemical research in toxicology 20050601

The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Naunyn-Schmiedeberg's archives of pharmacology 20050601

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

Movement disorders : official journal of the Movement Disorder Society 20050501

UDP-glucuronosyltransferases and clinical drug-drug interactions.

Pharmacology & therapeutics 20050401

The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050401

The combination of liquid chromatography/tandem mass spectrometry and chip-based infusion for improved screening and characterization of drug metabolites.

Rapid communications in mass spectrometry : RCM 20050101

Tolcapone: a review of its use in the management of Parkinson's disease.

CNS drugs 20050101

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

Expert opinion on drug safety 20050101

Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.

Movement disorders : official journal of the Movement Disorder Society 20050101

Oxidative stress mediated idiosyncratic drug toxicity.

Drug metabolism reviews 20050101

[Tolcapone treatment of late stages of Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101

[Comparison of the safety of the medicinal product in the European Union and the United States, tolcapone (Tasmar) -- COMT inhibitor as the analyzed example].

Neurologia i neurochirurgia polska 20050101

Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase.

Journal of medicinal chemistry 20041202

Assessment of catechol induction and glucuronidation in rat liver microsomes.

Drug metabolism and disposition: the biological fate of chemicals 20041201

Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.

The Cochrane database of systematic reviews 20041018

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

The Cochrane database of systematic reviews 20041018

Clinical advantages of COMT inhibition with entacapone - a review.

Journal of neural transmission (Vienna, Austria : 1996) 20041001

SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.

The Journal of pharmacology and experimental therapeutics 20040901

Drug treatment of Parkinson's disease.

Dialogues in clinical neuroscience 20040901

Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20040609

[Treatment in Parkinson disease].

Orvosi hetilap 20040411

Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.

Neuropharmacology 20040301

Safety and tolerability of COMT inhibitors.

Neurology 20040113

[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20040101

Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.

Experimental neurology 20030901

Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20030801

Prevention and treatment of motor fluctuations.

Parkinsonism & related disorders 20030801

The psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease.

Parkinsonism & related disorders 20030601

Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.

Expert opinion on drug safety 20030501

Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.

Drug metabolism and disposition: the biological fate of chemicals 20030301

Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.

The Journal of pharmacology and experimental therapeutics 20030201

Rapid screening and characterization of drug metabolites using a new quadrupole-linear ion trap mass spectrometer.

Journal of mass spectrometry : JMS 20030201

In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.

Chemical research in toxicology 20030201

The relevance of preclinical studies for the treatment of Parkinson's disease.

Journal of neurology 20030201

Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.

Parkinsonism & related disorders 20030101

Advances in the pharmacological management of Parkinson disease.

Journal of neural transmission. Supplementum 20030101

Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice.

Journal of applied toxicology : JAT 20030101

Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Drug safety 20030101

Mechanisms of idiosyncratic drug reactions: the case of felbamate.

Chemico-biological interactions 20021110

Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.

Journal of neural transmission (Vienna, Austria : 1996) 20021101

Effects of entacapone and tolcapone on mitochondrial membrane potential.

European journal of pharmacology 20021018

[The usefulness of dopaminergic drugs in traumatic brain injury].

Revista de neurologia 20020801

Entacapone in the management of Parkinson's disease.

Expert opinion on pharmacotherapy 20020701

Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20020701

Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.

Journal of neural transmission (Vienna, Austria : 1996) 20020501

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.

Synapse (New York, N.Y.) 20020301

Characterization of catechol glucuronidation in rat liver.

Drug metabolism and disposition: the biological fate of chemicals 20020201

Catechol-O-methyltransferase and Parkinson's disease.

Acta medica Okayama 20020201

Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase.

Journal of medicinal chemistry 20020131

COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20020101

Dopaminergic transmission in the rat striatum in vivo in conditions of pharmacological modulation.

Neuroscience and behavioral physiology 20020101

COMT inhibitors: management of Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20020101

DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20020101

Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity.

The pharmacogenomics journal 20020101

Approaching disturbed sleep in late Parkinson's Disease: first step toward a proposal for a revised UPDRS.

Parkinsonism & related disorders 20011001

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.

Movement disorders : official journal of the Movement Disorder Society 20010901

Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.

Journal of neuroscience methods 20010815

D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.

Kidney international 20010501

Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease.

Parkinsonism & related disorders 20010401

Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.

Molecular pharmacology 20010201

[Pharmacological treatments of Parkinson's disease].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010201

Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20010201

Possible applications for dopaminergic agents following traumatic brain injury: part 2.

The Journal of head trauma rehabilitation 20010201

Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.

Journal of neural transmission (Vienna, Austria : 1996) 20010101

Catechol-O-methyltransferase decreases levodopa toxicity in vitro.

Clinical neuropharmacology 20010101

The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.

Journal of neural transmission (Vienna, Austria : 1996) 20010101

Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.

Seminars in neurology 20010101

Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.

Clinical pharmacokinetics 20010101

Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.

European neurology 20010101

Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD.

Clinical neuropharmacology 20010101

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.

Clinical neuropharmacology 20010101

Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication.

European neurology 20010101

A preclinical re-evaluation of the safety profile of tolcapone.

Functional neurology 20010101

COMT inhibition and safety.

Functional neurology 20010101

Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.

Digestive diseases and sciences 20000901

Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.

Clinical pharmacology and therapeutics 20000601

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Drugs 20000601

Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.

The American journal of medicine 20000415

Tolcapone increases maximum concentration of levodopa.

Journal of neural transmission (Vienna, Austria : 1996) 20000101

Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.

European neurology 20000101

[Akathisia secondary to tolcapone. Report of a case].

Gaceta medica de Mexico 20000101

Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.

The Annals of pharmacotherapy 19991101

Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder.

Journal of clinical psychopharmacology 19990801

Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.

Brain research 19990306

Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.

Pharmacotherapy 19990101

Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.

Movement disorders : official journal of the Movement Disorder Society 19990101

Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.

Clinical neuropharmacology 19990101

Inhibition of catechol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: an in vitro electrophysiological evidence from rat mesencephalic dopamine neurons.

Journal of neural transmission (Vienna, Austria : 1996) 19990101

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

Archives of neurology 19980801

Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy.

European journal of clinical pharmacology 19980701

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.

Neurology 19980501

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.

Neurology 19970901

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.

Clinical pharmacology and therapeutics 19970901

Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.

British journal of pharmacology 19960201

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.

European journal of clinical pharmacology 19960101

Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.

Neuroscience letters 19950616

Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.

Clinical neuropharmacology 19950601

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.

Clinical pharmacology and therapeutics 19950501

Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.

Biochemistry 19950404

Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.

European journal of pharmacology 19950214

The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.

Experientia 19941015

Tolcapone: a potential new antidepressant detected in a novel animal model of depression.

Behavioural pharmacology 19940601

Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS.

Journal of neural transmission. Parkinson's disease and dementia section 19930101

Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease.

Journal of neural transmission. Parkinson's disease and dementia section 19900101

Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.

Journal of neural transmission. Supplementum 19900101